Epilepsy in cerebral amyloid angiopathy: an observational retrospective study of a large population

Payam Tabaee Damavandi1, Benedetta Storti1, Natalia Fabin2

  • 1Department of Neurology, ASST San Gerardo Hospital, School of Medicine and Surgery and Milan Center for Neuroscience, University of Milan-Bicocca, Monza, Italy.

Epilepsia
|December 14, 2022
PubMed

Insights

Epilepsy frequently develops in patients with cerebral amyloid angiopathy (CAA), particularly in those with CAA-related inflammation (CAA-ri) or cortical superficial siderosis (cSS). Identifying these risk factors aids in predicting and managing epilepsy in CAA patients.

Area of Science:

  • Neurology
  • Neuroscience
  • Geriatrics

Background:

  • Cerebral amyloid angiopathy (CAA) is a primary cause of spontaneous intracranial hemorrhage in the elderly.
  • Epilepsy is a potential complication of CAA, yet studies are limited, especially concerning CAA-related inflammation (CAA-ri).

Purpose of the Study:

  • To investigate the incidence and risk factors for epilepsy in patients with cerebral amyloid angiopathy (CAA).
  • To analyze epilepsy development in both inflammatory (CAA-ri) and non-inflammatory (CAA-nri) forms of CAA.

Main Methods:

  • A retrospective observational study of 96 CAA patients over 10 years.
  • Collected demographic, clinical, and instrumental data to identify epilepsy risk factors.
  • Calculated odds ratios and 95% confidence intervals for risk factor analysis.

Main Results:

  • 34.4% of CAA patients developed epilepsy, with focal seizures being most common (81.3%).
  • Cortical superficial siderosis (cSS) increased epilepsy risk in CAA-nri; CAA-ri was associated with epilepsy in the overall cohort.
  • Electroencephalography showed abnormalities in both epileptic and non-epileptic patients.

Conclusions:

  • Epilepsy is a common outcome in cerebral amyloid angiopathy (CAA) patients.
  • CAA-related inflammation (CAA-ri) and cortical superficial siderosis (cSS) are significant predisposing factors for seizures.
  • Detailed patient characterization is crucial for identifying individuals at higher risk of developing epilepsy.
Abstract